Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | MPO | P05164 | 1/20 | 0.59 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.59 |
| ▸ | NSD2 | O96028 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | PRNP | P04156 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4674283 | 0.87 | POLB (0.69) | POLBKMT2AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL10762447 | 0.86 | KMT2A (0.73) | POLBKMT2AALDH1A1HSD17B10HPGD | |
| SCHEMBL5266012 | 0.85 | NPSR1 (0.69) | POLBKMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL15353949 | 0.84 | KMT2A (0.66) | POLBKMT2AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL9431194 | 0.84 | MAPT (0.67) | POLBKMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4677466 | 0.84 | POLB (0.65) | POLBKMT2AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4677462 | 0.84 | POLB (0.65) | POLBKMT2AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL16181940 | 0.83 | ALDH1A1 (0.70) | POLBKMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL28382106 | 0.83 | ALDH1A1 (0.61) | POLBKMT2AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL7867868 | 0.83 | MAPT (0.66) | POLBKMT2AKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2083819-B1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORP (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2083819-B1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORP (US) | 2017-02-22 | — | — | EP | disclosed |
| US-8278327-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278327-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110245231-A1 | ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCE, AND A METHOD FOR OBTAINING AND THE USE OF SAID ACTIVE SUBSTANCE | ALLA CHEM, LLC (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245231-A1 | ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCE, AND A METHOD FOR OBTAINING AND THE USE OF SAID ACTIVE SUBSTANCE | ALLA CHEM, LLC (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110021509-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021509-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-01-27 | — | — | US | disclosed |
| US-7786139-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786139-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080300240-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300240-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008064342-A2 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2008-05-29 | — | — | WO | disclosed |
| EP-1896048-A2 | PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP) RECEPTOR (VPAC2) AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | Bayer Pharmaceuticals Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1883419-A2 | GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | Bayer Pharmaceuticals Corporation (US) | 2008-02-06 | — | — | EP | disclosed |
| WO-2006121588-A2 | PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP) RECEPTOR (VPAC2) AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121904-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121860-A2 | GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006091506-A2 | NEUROPEPTIDE Y4 RECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006049681-A2 | SELECTIVE NEUROPEPTIDE Y2 RECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300240-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | POLB 1149/4885KMT2A 2226/4885KDM4E 2347/4885 |
| US-20110245231-A1 | ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCE, AND A METHOD FOR OBTAINING AND THE USE OF SAID ACTIVE SUBSTANCE | ADH1C, ADH1A, ADH5 | POLB 3103/4885KMT2A 1858/4885KDM4E 2280/4885 |
| US-20110021509-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | POLB 1190/4885KMT2A 2232/4885KDM4E 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.